1 / 27

Nasal Systems

Novel delivery systems for treating Type 1 diabetes. Nasal Systems. Han Yi Chua Gek Huey. Outline. Rationale System description Evidence for efficacy Stage of development. Rationale. Improving patient compliance compared with parenteral routes

kamali
Télécharger la présentation

Nasal Systems

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novel delivery systems for treating Type 1 diabetes Nasal Systems Han Yi Chua Gek Huey

  2. Outline • Rationale • System description • Evidence for efficacy • Stage of development

  3. Rationale • Improving patient compliance compared with parenteral routes • Large absorptive surface area and the high vascularity of the nasal mucosa • Avoiding hepato-gastrointestinal first-pass metabolism • Similar plasma pharmacokinetics (PK) profile to intravenous injection • Mimicing pulsatile secretion pattern of insulin

  4. Nasal cavity anatomy Increased absorption area turbinates Epithelia monolayer High permeability & rapid absorption

  5. Structure of nasal mucosa • Mucociliary clearance – cilia & mucus • Insoluble particles removed before being absorbed • Gases/solution penetrate further into respiratory tract

  6. Barriers to intranasal insulin absorption • Removal of deposited insulin by mucociliary clearance • Difficulty of penetrating mucus layer and epithelial membrane • Enzymatic degradation

  7. Removal of deposited insulin by mucociliary clearance • Mucociliary mechanism t1/2 of clearance is only 15-30min decreases time available for drugs to be systemically absorbed • Size of particles suitable for nasal delivery particle aerodynamic diameter: 1-10µm

  8. Penetration of mucus layer and epithelial membrane • Mucus layer Drugs may interact with mucus glycoproteins • Epithelial membrane Lipophilic compounds via transcellular route Hydrophilic compounds (MW< 1000 daltons) via paracellular route

  9. Enzymatic degradation • Nasal cavity is still a significant barrier although intranasal route avoids first pass metabolism

  10. System modification • Absorption enhancers or promoters most frequently used approach • Modification of the structure of insulin

  11. Formulation types in current research • Spray • Drop • Powder

  12. 1922 1931 1932 1935/6 • Major[123,124] • Uses glycols • Normal rabbits, dogs and diabetic patients • Marked decreases in blood glucose conc. • high dosage: 100IU nasal • Poor reproducibility of hypoglycaemic control Woodyatt[23] Fail to generate positive results Horwitz[121] Failed to demonstrate insulin absorption thru nasal route • Collens[122] • Uses saponin (natural glycoside surfactant) • 100IU nasal  10IU subcutaneous injection • Causes nasal congestion & • symptoms of rhinitis Evidence of efficacy (I)

  13. 1958 • Hankiss[125] • Nasal tampons (increased contact time) • Healthy volunteers and diabetic patients • 53% that of subcutaneous injection • No absorption promoter used • Unstable & variable • Efficacy calculated 60 mins after administration (subcutaneous injection had not reached nadir) Evidence of efficacy (II)

  14. Bile salts SGC SDC STDHF 1977 1983 1987 1988 1989 1994 Laureth-9 Surfactants LPC DDPC LPG Fatty acids Evidence of efficacy (III)

  15. Bioadhesive Carbopol Starch microshperes Chitosan 1985 1988 1996 • Chitosan • Rel. Bioavailability (subcutaneous)= 15% • Rel. Bioavailability (intravenous) = 7% • Starch microspheres: • 30% to intravenous dose • Abs bioavailability = 4.5% • Starch microshperes with LPC: • Abs. bioavailability = 13% • Rel. bioavailability (intravenous)= 32% Evidence of efficacy (IV)

  16. Requirements of enhancer • Rapid-acting • Transient & reversible modulation • Not absorbed systemically • Predictable & reproducible degree of absorption enhancement • Safe for chronic nasal administration • Open tight junction, disrupt membrane

  17. Nasal absorption promoting system

  18. Systemic insulin absorption after intranasal administration to humans

  19. Problems with enhancers

  20. Modification of structure • Lys(B28)Pro(B29) insulin analogues [Merkus, 1996] • Powder formulation with cyclodextrin • Chemical modification with fatty acids [Asada, 1992] • Enhance lipophilicity • Pharmacological availability decreased

  21. Stage of development • Bentley Pharmaceuticals (BNT) 02 Feb 2004 • Phase I clinical trial using proprietary intranasal insulin formulation in human volunteers http://www.biospace.com/ccis/news_story.cfm?StoryID=15018420&full=1 Successful Phase I Study Of Intranasal Insulin In Human Volunteers End

  22. Bioadhesive • Interacts with mucosal layer Back

  23. Chitosan • Enhance via paracellular route due to interaction of negatively charged epithellial cells resulting in structural changes in tight junction associated protein • Increase membrane permeability • Bioavailability abt 15% relative to subcutaneous; 7% relative to intravenous • Does not cause change in saccharin clearance times • No adverse effect in nasal cilia beat frequency • Non-damaging to biomembranes • Reversible reduction in nucociliary transport rate (MTR) Back

  24. Bile Salts • Amphiphilic molecules • Possess distinct non-polar and polar regions • critical micellar concentration • Arrest cilia beat frequency • Damage nasal mucosa Back

  25. Surfactants • Lower surface and interfacial tension of water • Promote association into micelles • Modify properties of biological membranes • Alter their permeability and transport characteristics Back

  26. Fatty acids • Organic compounds which are principal component of most lipids and consist mainly of straight chains of an even number of carbon atoms Back

More Related